The FDA has approved a female Viagra pill for use by women in the States -- so now there's a little pink pill to match the little blue one.
Addyi doesn't function like Viagra does but because of the ubiquity of the brand name, it's being called the female Viagra pill. While Viagra targets a physical issue and is a single-use drug, Addyi is taken regularly and affects one's central nervous system and brain chemistry. In fact, it was initially developed as a treatment for depression.
According to Sprout Pharmaceuticals -- the company responsible for the female Viagra pill -- women taking Addyi experience a 37% increase in sexual desire. The drug is intended for premenopausal women with low sex drives. It will be interesting to see if the female Viagra pill becomes as successfully mainstreamed as its little blue counterpart.
What Makes This Trend Stand Out
- Female Viagra Pill
- The FDA approval for a female Viagra pill presents an opportunity for disruptive innovation in the field of women's sexual health.
- Increase in Sexual Desire
- The 37% increase in sexual desire experienced by women taking Addyi opens up possibilities for innovative solutions to address low libido in women.
- Mainstreaming Female Sexual Health
- The potential mainstream success of the female Viagra pill suggests an opportunity to disrupt the market by catering to women's sexual health needs.
Sectors Adopting This
- Pharmaceuticals
- The approval of the female Viagra pill creates a new market for pharmaceutical companies to develop innovative medications for women's sexual health.
- Mental Health
- The use of Addyi, initially developed as a treatment for depression, highlights the potential for disruptive innovation in the intersection of mental health and sexual wellness.
- Wellness and Self-care
- The introduction of the female Viagra pill paves the way for disruptive innovation in the wellness industry, focusing on enhancing women's sexual satisfaction and overall well-being.
